Search

Alkermes PLC

Nyitva

SzektorEgészségügy

46.35 3.18

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

44.83

Maximum

46.52

Fő mutatók

By Trading Economics

Bevétel

67M

501K

Értékesítés

103M

496M

P/E

Szektor átlag

118.132

51.78

Egy részvényre jutó nyereség

0.57

Profit margin

0.101

Munkavállalók

2,050

EBITDA

76M

54M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+34.51% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-1.3B

7.5B

Előző nyitás

43.17

Előző zárás

46.35

Alkermes PLC Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. nov. 4. 21:07 UTC

News

RBC Capital raised its price target on Alkermes Plc to $57, maintaining an Outperform rating, while H.C. Wainwright increased its target to $50.

2026. nov. 3. 23:01 UTC

Alkermes Plc is declining in after-market trading, retreating significantly from earlier gains.

2026. nov. 2. 21:04 UTC

Event

Alkermes initiates a phase 2 study for ALKS 7290 as an adjunctive therapy for major depressive disorder, amid broader market declines.

2026. okt. 29. 20:06 UTC

Alkermes Plc shares are advancing, showing a modest gain since Wednesday's close and remaining notably above their 20-day moving average.

2026. okt. 28. 20:52 UTC

Alkermes Plc shares are trading modestly lower in after-market hours, reflecting the broader market's significant decline amid recent economic data and the Fed's cautious outlook.

2026. okt. 27. 19:46 UTC

Alkermes Plc shares fell modestly after retracing from an early high, though they remain above the 20-day moving average and near the upper end of their one-month range.

2026. okt. 26. 19:46 UTC

Alkermes Plc is trading higher, showing strength above its 20-day moving average and near the upper end of its one-month range.

2026. okt. 23. 20:07 UTC

Alkermes Plc shares fell amid a broader market decline, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

2026. okt. 22. 20:07 UTC

Alkermes Plc shares advanced, trading higher after Wednesday's close, despite pulling back from a session high earlier in the day.

2026. okt. 21. 20:01 UTC

Alkermes Plc shares fell sharply after reaching an early high, declining to their lowest point before 3:30 PM.

2026. okt. 20. 20:08 UTC

Alkermes Plc is trading higher, maintaining gains since Monday, despite pulling back from earlier session highs, and remains above its 20-day moving average.

2026. okt. 19. 20:01 UTC

News

Piper Sandler reiterates Overweight rating on Alkermes and sets price target at $65 following management meetings.

2026. okt. 17. 00:02 UTC

Alkermes Plc's shares advanced modestly in after-market trading on Friday, following three consecutive higher daily closes and a notable rise during the session.

2026. okt. 16. 23:31 UTC

Alkermes Plc has advanced in after-market trading, reaching its highest level since Friday's close, continuing a stronger trend from recent sessions.

2026. okt. 15. 20:01 UTC

Alkermes Plc shares are advancing, having gained since Wednesday's close, peaking nearly 4% earlier before pulling back slightly.

2026. okt. 14. 20:07 UTC

Event

Alkermes plans to present two oral presentations and six posters at the European Sleep Research Society’s Congress in October 2026.

2026. okt. 12. 19:16 UTC

Alkermes Plc shares fell, continuing a trend of weakness, and are positioned below their 20-day moving average near the lower end of their one-month range.

2026. okt. 9. 21:51 UTC

Alkermes Plc is declining in after-market trading, reaching its lowest point since Friday's close and remaining significantly below its 20-day moving average.

2026. okt. 8. 20:01 UTC

Alkermes Plc shares fell, reversing a trend of higher daily closes amid a broader shift in market performance.

2026. okt. 7. 19:25 UTC

Alkermes Plc shares fell modestly, retracing from a late morning high, contributing to a lower performance since Tuesday's close and remaining below the 20-day moving average.

2026. okt. 6. 19:51 UTC

Alkermes Plc shares fell sharply, continuing a notable decline since Monday's close amid broader market conditions and trading below its 20-day moving average.

2026. okt. 5. 23:40 UTC

Alkermes Plc is trading higher in after-market hours, extending its upward trend after three consecutive sessions of gains amid positive biotechnology sector performance.

2026. okt. 2. 19:26 UTC

Alkermes Plc is trading sharply higher, recovering from earlier lows, despite remaining below its 20-day moving average and near the lower end of its one-month range.

2026. okt. 1. 22:50 UTC

Alkermes Plc declined in after-market trading, moving lower since Thursday's close and positioning the stock below its 20-day moving average.

2026. szept. 29. 20:07 UTC

Alkermes Plc closed higher in Tuesday's trading session, despite notable volatility, finishing above Monday's close but below its 20-day moving average.

2026. szept. 28. 19:16 UTC

News

Alkermes Plc shares fell modestly, continuing a decline since Friday and trading near the lower end of their one-month range.

2026. szept. 24. 20:01 UTC

News

Alkermes Plc shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a $50.00 price target, contributing to the stock's decline.

2026. szept. 23. 20:07 UTC

Alkermes Plc shares fell sharply today, hitting a midday low and remaining below the 20-day moving average after earlier strength in the session.

2026. szept. 22. 20:01 UTC

Event

Alkermes Plc reported positive results from a phase 1 study for ALKS 7290, yet shares fell sharply, remaining below their 20-day moving average.

2026. szept. 21. 23:51 UTC

Event

Alkermes Plc's stock is declining in after-market trading despite positive phase 1 results for ALKS 7290, remaining below its 20-day moving average.

Társak összehasonlítása

Árváltozás

Alkermes PLC Előrejelzés

Célár

By TipRanks

34.51% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 61.727 USD  34.51%

Magas 83 USD

Alacsony 50 USD

13 Wall Street elemző 12 hónapos célárain alapulva a(z)Alkermes PLC termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

13 ratings

9

Vétel

3

Tartás

1

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat